BNOX Bionomics Limited

12.42
+0.41  (+3%)
Previous Close 12.01
Open 12.92
52 Week Low 10.53
52 Week High 22
Market Cap $93,381,198
Shares 7,518,615
Float 7,518,615
Enterprise Value $77,408,781
Volume 3,062
Av. Daily Volume 10,289
Stock charts supplied by TradingView

Upcoming Catalysts

Drug Stage Catalyst Date
BNC210 - (PREVAIL)
Social Anxiety Disorder (SAD)
Phase 2
Phase 2
Premium membership is required to view catalyst dates, analyst ratings, earnings dates and cash burn data. Click here to unlock and sign up to a 14-day FREE TRIAL.
BNC210 - (ATTUNE)
Post-Traumatic Stress Disorder (PTSD)
Phase 1
Phase 1
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien.

Drug Pipeline

Drug Stage Notes
α7 Receptor PAM
Alzheimer's Disease
Phase 1
Phase 1
Phase 1 safety and biomarker studies ongoing, noted January 11, 2022.

Latest News

  1. EASTWOOD, Australia, Jan. 14, 2022 /PRNewswire/ -- Bionomics Limited (NASDAQ:BNOX, ASX: BNO))), a clinical-stage biopharmaceutical developing novel, allosteric ion channel modulators designed to transform the lives of patients suffering from serious central nervous system disorders with high unmet medical need, will ring the Nasdaq Closing Bell remotely from around the globe.

    Dr Errol De Souza, Executive Chairman, will ring the Closing Bell alongside the Company's team in a virtual bell ringing ceremony.

    When:
    FRIDAY, JANUARY 14, 2021 – 3:45 p.m. to 4:00 p.m. ET 

    Webcast:
    A live stream of the Nasdaq Closing Bell will be available at: https://www.nasdaq.com/marketsite/bell-ringing-ceremony  

    Social Media:
    For multimedia features such as exclusive…

    EASTWOOD, Australia, Jan. 14, 2022 /PRNewswire/ -- Bionomics Limited (NASDAQ:BNOX, ASX: BNO))), a clinical-stage biopharmaceutical developing novel, allosteric ion channel modulators designed to transform the lives of patients suffering from serious central nervous system disorders with high unmet medical need, will ring the Nasdaq Closing Bell remotely from around the globe.

    Dr Errol De Souza, Executive Chairman, will ring the Closing Bell alongside the Company's team in a virtual bell ringing ceremony.

    When:

    FRIDAY, JANUARY 14, 2021 – 3:45 p.m. to 4:00 p.m. ET 

    Webcast:

    A live stream of the Nasdaq Closing Bell will be available at: https://www.nasdaq.com/marketsite/bell-ringing-ceremony  

    Social Media:

    For multimedia features such as exclusive content, photo postings, status updates and video of bell ceremonies, please visit our Facebook page: http://www.facebook.com/nasdaq

    For photos from ceremonies and events, please visit our Instagram page: http://instagram.com/nasdaq

    Photos:

    To obtain a hi-resolution photograph of the Market Close, please go to https://www.nasdaq.com/marketsite/bell-ringing-ceremony  and click on the market close of your choice.

    FOR FURTHER INFORMATION PLEASE CONTACT:

    General:

    Ms Suzanne Irwin

    Company Secretary

    +61 8 8150 7400

     

    Investor Relations:

    Mr. Connor Bernstein

    Vice President, Strategy and Corporate Development

    +1 (831) 246 3642

    About Bionomics Limited:

    Bionomics (NASDAQ:BNOX, ASX:BNO))) is a clinical-stage biopharmaceutical developing novel, allosteric ion channel modulators designed to transform the lives of patients suffering from serious central nervous system disorders with high unmet medical need. Bionomics is advancing its lead product candidate, BNC210, an oral, proprietary, selective negative allosteric modulator of the α7 nicotinic acetylcholine receptor, for the acute treatment of Social Anxiety Disorder and chronic treatment of Post-Traumatic Stress Disorder. Beyond BNC210, Bionomics has a strategic partnership with Merck & Co., Inc. (known as MSD outside the United States and Canada) with two drugs in early-stage clinical trials for the treatment of cognitive deficits in Alzheimer's disease and other central nervous system conditions.  To learn more about the company, technology solutions and career opportunities, visit us on LinkedIn, on Twitter @Bionomics1, or at www.bionomics.com.au.

    About Nasdaq:

    Nasdaq (NASDAQ:NDAQ) is a global technology company serving the capital markets and other industries. Our diverse offering of data, analytics, software and services enables clients to optimize and execute their business vision with confidence. To learn more about the company, technology solutions and career opportunities, visit us on LinkedIn, on Twitter @Nasdaq, or at www.nasdaq.com.

    Cision View original content:https://www.prnewswire.com/news-releases/bionomics-limited-nasdaq-bnox-asx-bno-to-ring-the-nasdaq-stock-market-closing-bell-on-friday-january-14-2022-301461190.html

    SOURCE Bionomics Limited

    View Full Article Hide Full Article
  2. ADELAIDE, Australia, Jan. 12, 2022 /PRNewswire/ -- Bionomics Limited ((ASX:BNO, NASDAQ:BNOX) (Bionomics or Company), a clinical-stage biopharmaceutical company, participated in the H.C Wainwright BioConnect Conference that was held virtually from January 10-13, 2022.

    Dr Errol De Souza, Executive Chairman of Bionomics, provided an update on the Company including BNC210, an oral, proprietary, selective negative allosteric modulator of the α7 nicotinic acetylcholine receptor in development for the acute treatment of Social Anxiety Disorder (SAD) and chronic treatment of Post-Traumatic Stress Disorder (PTSD), with U.S. Food and Drug Administration (FDA) Fast Track designation for both clinical indications.

    The presentation is available on the Company's…

    ADELAIDE, Australia, Jan. 12, 2022 /PRNewswire/ -- Bionomics Limited ((ASX:BNO, NASDAQ:BNOX) (Bionomics or Company), a clinical-stage biopharmaceutical company, participated in the H.C Wainwright BioConnect Conference that was held virtually from January 10-13, 2022.

    Dr Errol De Souza, Executive Chairman of Bionomics, provided an update on the Company including BNC210, an oral, proprietary, selective negative allosteric modulator of the α7 nicotinic acetylcholine receptor in development for the acute treatment of Social Anxiety Disorder (SAD) and chronic treatment of Post-Traumatic Stress Disorder (PTSD), with U.S. Food and Drug Administration (FDA) Fast Track designation for both clinical indications.

    The presentation is available on the Company's website https://www.bionomics.com.au/investor-centre/presentations-posters/

    FOR FURTHER INFORMATION PLEASE CONTACT:

    General:

    Investor Relations:

    Ms Suzanne Irwin

    Mr. Connor Bernstein

    Company Secretary

    Vice President, Strategy and Corporate Development

    +61 8 8150 7400

    +1 (831) 246-3642

     

    About Bionomics Limited

    Bionomics is a clinical-stage biopharmaceutical company developing novel, allosteric ion channel modulators designed to transform the lives of patients suffering from serious central nervous system disorders with high unmet medical need. Bionomics is advancing its lead product candidate, BNC210, an oral, proprietary, selective negative allosteric modulator of the α7 nicotinic acetylcholine receptor, for the acute treatment of Social Anxiety Disorder and chronic treatment of Post-Traumatic Stress Disorder. Beyond BNC210, Bionomics has a strategic partnership with Merck & Co., Inc. (known as MSD outside the United States and Canada) with two drugs in early-stage clinical trials for the treatment of cognitive deficits in Alzheimer's disease and other central nervous system conditions.

    www.bionomics.com.au

    Cision View original content:https://www.prnewswire.com/news-releases/bionomics-limited-participated-in-the-hc-wainwright-bioconnect-conference-301459281.html

    SOURCE Bionomics Limited

    View Full Article Hide Full Article
View All Bionomics Limited News